Lower-dose edoxaban in elderly people with atrial fibrillation and past stroke
Compares two edoxaban doses in people aged 80 or older with atrial fibrillation.
Plain-language title generated from the registry record
Registry title: Low Dose Edoxaban in Elderly Patients With AF and a History of Stroke
Key facts
- Where
- Taipei, TaiwanSee the site
- Phase
- Phase 2/3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 80 or older with atrial fibrillation and a past ischemic stroke or transient ischemic attack, who also have a higher risk of bleeding.
- Age
- 80 years or older
- Sex
- All sexes can join.
- Disease stage
- Atrial fibrillation with a history of ischemic stroke or transient ischemic attack.
- Earlier treatment
- People who recently used anticoagulants cannot join: warfarin within 1 month, or heparin, low molecular weight heparin or direct oral anticoagulants within 7 days before enrollment.
Main reasons for not taking part
- Recent use of warfarin, heparin, low molecular weight heparin or direct oral anticoagulants
- Allergy to edoxaban
- Regular dialysis (hemodialysis or peritoneal dialysis)
- Refusing to give informed consent
Read by machine on 12 November 2026.
Where in Taiwan
- National Taiwan University HospitalTaipei, TaiwanContact: Shin Yi LinNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- National Taiwan University Hospital
- Trial code
- NCT06900725
- Record updated
- 2 April 2025
- Original description
This prospectively enrolled, pragmatic randomized trial aims to investigate whether very low dose edoxaban regimen (15 mg daily) achieves similar edoxaban concentrations as low dose edoxaban regimen (30 mg daily), while maintaining a comparable risk of clinical outcomes and reducing major bleeding in elderly patients with atrial fibrillation and a history of ischemic stroke or transient ischemic attack.Read full original descriptionShow less
Low-Dose Edoxaban Versus Very-Low-Dose Edoxaban in Elderly Patients With Atrial Fibrillation and a History of Stroke (LEAVE-Stroke): A Pragmatic Randomized Clinical Trial
This prospectively enrolled, pragmatic randomized trial aims to investigate whether very low dose edoxaban regimen (15 mg daily) achieves similar edoxaban concentrations as low dose edoxaban regimen (30 mg daily), while maintaining a comparable risk of clinical outcomes and reducing major bleeding in elderly patients with atrial fibrillation and a history of ischemic stroke or transient ischemic attack.
Inclusion: Age>=80 years; Has been diagnosed atrial fibrillation; Has history of ischemic stroke or transient ischemic attack; Has any of the bleeding risk lists below; bodyweight < 60 kg; creatinine clearance < 50 mL/min; history of major bleeding or gastrointestinal bleeding; concurrent use of antiplatelet agents (such as aspirin, clopidogrel, ticagrelor, prasugrel, cilostazol), non-steroidal anti-inflammatory drugs, amiodarone, tacrolimus, cyclosporine, dronedarone.
Exclusion: warfarin therapy within 1 month before study enrollment; using heparin, low molecular weight heparin or direct oral anticoagulants within 7 days before study enrollment; allergy to edoxaban; Has ever used anticoagulants, defined as:; under regular dialysis, includes hemodialysis or peritoneal dialysis; refuse to provide informed consent.